MwanzoSYGGF • OTCMKTS
add
Synairgen Ord Shs
Bei iliyotangulia
$ 0.0085
Bei za mwaka
$ 0.0085 - $ 0.090
Thamani ya kampuni katika soko
11.03M GBP
Wastani wa hisa zilizouzwa
elfu 2.89
Uwiano wa bei na mapato
-
Mgao wa faida
-
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 1.95M | -29.14% |
Mapato halisi | -1.63M | 31.28% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | — | — |
EBITDA | -1.95M | 28.75% |
Asilimia ya kodi ya mapato | 10.92% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 8.59M | -19.19% |
Jumla ya mali | 10.64M | -43.12% |
Jumla ya dhima | 1.08M | -60.69% |
Jumla ya hisa | 9.56M | — |
hisa zilizosalia | 201.37M | — |
Uwiano wa bei na thamani | 0.17 | — |
Faida inayotokana na mali | -45.90% | — |
Faida inayotokana mtaji | -51.07% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -1.63M | 31.28% |
Pesa kutokana na shughuli | -1.84M | 30.36% |
Pesa kutokana na uwekezaji | elfu 882.00 | 88,100.00% |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | elfu -962.50 | 63.64% |
Mtiririko huru wa pesa | -1.13M | 24.89% |
Kuhusu
Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic. The company is developing an inhaled formulation of interferon-beta for severe viral respiratory diseases including COVID-19.
Richard Marsden was appointed chief executive officer in September 2009. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2003
Tovuti
Wafanyakazi
36
